Bisphosphonates have been shown to be effective in treating the increased bone turnover associated with Paget's disease of bone. In this study two groups of patients were treated with pamidronate by intravenous infusion. In group 1 (n= 15) 30 mg of pamidronate was given once a week for six weeks. A subgroup (group IA, n=6) of more severely affected patients (pretreatment serum alkaline phosphatase (ALP) >1000 U/i, normal range 80-280 U/i) received a further 60 mg weekly for three weeks. Group 2 (n=24) received 45 mg of pamidronate every three months for one year.
for three weeks. Group 2 (n=24) received 45 mg of pamidronate every three months for one year.
In both groups the level of ALP in serum samples decreased steadily throughout the year. In group 1 the level decreased to a mean value of 230 U/I (95% confidence interval 188-281) and in group 2 to 297 U/i (227-389). Four of the six patients in group 1A achieved normal ALP, whereas ALP remained at an increased level in ali of the 10 patients in group 2 whose pretreatment ALP was >1000 U/i, suggesting that a dose-response effect exists. The lowest hydroxyproline to creatinine ratios (normal ratio <0.033) were observed at the end of treatment in group 1, with a mean ratio of 0-022 (range 0-015-0.033) and at three months after the start of treatment in group 2 with a mean ratio of 0-029 (range 0.022-0.037).
There was a significant decrease in the turnover of bone, as measured by whole body retention of radiolabelied bisphosphonate, from a mean of 49-3 to 41-0% (p<001).
These data confirm that pamidronate is effective in the management of Paget's disease of bone. For patients with levels of ALP in serum samples of up to four times above the upper limit of the normal reference range, an effective and convenient regimen is 45 mg every three months for one year. For patients with 24 patients who received infusions of 45 mg pamidronate every three months for one year, irrespective of their serum alkaline phosphatase levels. The total dose of pamidronate given was the same in both groups, i.e. 180 mg, although group IA received a total dose of 360 mg. All infusions were given in 500 ml 0-9% saline and infused intravenously A random group of six of these patients was given placebo infusions of 0-9% saline weekly for three weeks at the start of treatment in a single-blind study. These six patients then received pamidronate as described above.
Biochemical variables were measured in group 1 patients after one month of treatment, at the end of treatment, at six months, and at one year. In group 2 patients measurements were made at intervals of three months throughout the study. Serum ALP activity was measured by an autoanalyser (Technicon, Tarrytown, USA), urinary hydroxyproline by resin catalysed hydrolysis,22 followed by autoanalyser quantitation, and urinary creatinine by an autoanalyser (Technicon). Urine samples were collected as second voided morning samples after fasting and the results expressed as hydroxyproline tocreatinineratios (normalratio <0*033).
Bone turnover was also determined before treatment and after one year by the 24 hour whole body retention of methylene bisphosphonate labelled with technetium-99m. 23 Every patient gave verbal informed consent before beginning treatment and this study was approved by the local hospital ethical committee.
As the data were skewed, they were logarithmically transformed and a Student's t test was used to assess changes within the group. One way analysis of variance was used to assess changes between different treatment groups. Correlations were carried out using Spearman rank coefficients. The maximum decrease in the hydroxyproline to creatinine ratio (fig 3) occurred at the end of treatment in group 1, with a mean of 0-022 U/i (0-015-0-033, p<0-001), and at three months after the start of treatment in group 2, with a mean of 0-029 U/I (0-022-0-037, p<0.003). In two patients in group 1 and five patients in group 2, the hydroxyproline to creatinine ratio remained raised.
There was a significant positive correlation between ALP level and the hydroxyproline to creatinine ratio in urine before (r=0-63, p=00002) and after treatment (r=0-41, p=001). One way analysis of variance gave no statistically significant difference between groups 1 and 2.
A significant overall improvement in symptoms, assessed by visual analogue pain scores, was seen during treatment. Where placebo infusions were given there was little change in pain scores, although these did subsequently improve (after three weeks) when the patients received the active drug.
There was a general decrease in tracer uptake in radionuclide bone scans after treatment, although this was not always seen. In some patients the tracer uptake was increased in some areas and, in the same patient, decreased in others.
There was a significant decrease in the whole There are some features of this study which are interesting and unexpected. In a small number of patients the urinary excretion of hydroxyproline increased to greater than the pretreatment levels. In these patients the level of ALP in serum samples decreased. Although it is possible that this decrease may be caused by the relative inhibition of mineralisation caused by pamidronate, the concurrent decrease in the whole body retention of radiolabelled bisphosphonate suggests that it is more likely that bone turnover has been reduced and that these urine concentrations reflect the difficulty in obtaining true fasting samples from outpatients. This variability in hydroxyproline excretion has been noted previously in Paget's disease treated with pamidronate.25 The hydroxyproline to creatinine ratios began to increase after the end of treatment (group 1) or after three months (group 2). This is particularly surprising in group 2 as further treatment with pamidronate was being given to these patients. This may either be due to an 'escape' phenomenon, or it may be that there is a subgroup of osteoclasts that are relatively resistant to pamidronate.
Although there was a general reduction in tracer uptake in bone scans after treatment, this was not always seen and occasionally a lesion took up more of the radionucide. This may also suggest that there are pagetic lesions present which are relatively resistant to treatment.
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